Is Biotest AG (BIESF) a Buy, Sell, or Hold?
Biotest AG
OTC:BIESF
$32 USD
$0 (0.0%)
- Volume
- 100
- Average Volume
- 75
- Market Capitalization
- $1.6B
- P/E Ratio
- 48.06
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $32.00
- Year Low
- $30.48
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.06
- Current Ratio
- $5.06
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Jorg Schuttrumpf |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BIESF |
| CUSIP | None |
| CIK | None |
| Web | https://www.biotest.com |
| Phone | 49 61 03 801 0 |
| Currency | USD |
| Employees | 2495 |
| Country | DE |
Liquidity
| Debt-to-Equity Ratio | 1.13 |
| Payout Ratio | 0.06 |
| Current Ratio | 5.06 |
| Quick Ratio | 2.06 |
| Cash Ratio | 0.67 |
Sales & Book Value
| Annual Sales | $648.66M |
| Price / Sales | 2.18 |
| Cash Flow | 0.81 |
| Price / Cash Flow | 49.19 |
| Price / Book | 2.40 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.79 |
| Trailing P/E Ratio | 48.06 |
| PEG Ratio | -0.42 |
| P/E Growth | -0.42 |
| Net Income | $-70.67M |
| Net Margin | 3.64% |
| Pretax Margin | 6.40% |
| Return on Equity | 5.13% |
| Return on Assets | 1.84% |
Financials Score
| AltmanZ Score | 2.17 |
| Piotroski Score | 4.00 |
| Working Capital | 628.6M |
| Total Assets | 1.42B |
| Ebit | 5.5M |
| Market Cap | 1.4B |
| Total Liabilities | 906.9M |
Poll Results
About Biotest AG (OTC:BIESF) Stock
Biotest Aktiengesellschaft, a German biopharmaceutical company established in Dreieich in 1946, specializes in the research, development, production, and global commercialization of advanced biological therapeutics. Its operations are organized into key segments: Therapy, Plasma & Services, and Other. The company’s primary focus areas encompass critical medical needs within hematology (blood disorders), clinical immunology, and intensive care medicine. Biotest offers a comprehensive range of products, including specific treatments for hemophilia like Haemoctin and Vihuma for the acute and prophylactic management of hemophilia A, and Haemonine for similar applications in hemophilia B. Its portfolio also features immunotherapies such as Cytotect CP biotest for cytomegalovirus infections, Fov ... epta for hepatitis B prophylaxis in neonates, and Hepatect for preventing hepatitis B reinfection. Varitect addresses varicella zoster virus infections, while Intratect and IgG Next Generation are utilized for primary immune and secondary antibody deficiency syndromes, autoimmune conditions, and certain neurological indications. Additionally, Zutectra is available for hepatitis B re-infection prophylaxis following liver transplantation. Further extending its product line, Biotest provides solutions like Albiomin and Biseko to restore and sustain circulating blood volume, Cofact for clotting factor deficiencies, and Fibrinogen for congenital fibrinogen deficiency. Innovative treatments include Trimodulin for community-acquired pneumonia and COVID-19, as well as Pentaglobin for bacterial infections. Known as Biotest Serum-Institut GmbH until its renaming in 1986, the company has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
Frequently Asked Questions
-
What is the current Biotest AG (BIESF) stock price?
-
Biotest AG(OTC:BIESF) stock price is $32 in the last trading session. During the trading session, BIESF stock reached the peak price of $32 while $30.48 was the lowest point it dropped to. The percentage change in BIESF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BIESF stock was $0.
-
BIESF's industry and sector of operation?
-
The OTC listed BIESF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BIESF?
-
Christina Erb | Head of Corporate HR
Jorg Schuttrumpf | Chief Executive Officer & Chairman of Management Board
Monika Buttkereit | Head of Investor Relations
Dirk Schuck | Employee Representative Member of Supervisory Board
| -
How many employees does BIESF have?
-
Number of BIESF employees currently stands at 2495. BIESF operates from Landsteinerstrasse 5, Dreieich, None 63303, DE.
-
Link for BIESF official website?
-
Official Website of BIESF is: https://www.biotest.com
-
How do I contact BIESF?
-
BIESF could be contacted at phone #49 61 03 801 0 and can also be accessed through its website. BIESF operates from Landsteinerstrasse 5, Dreieich, None 63303, DE.
-
How many shares of BIESF are traded daily?
-
The average number of BIESF shares traded daily for last 3 months was 75.
-
What is the market cap of BIESF currently?
-
The market value of BIESF currently stands at $1.6B with its latest stock price at $32